Skip to content

Author

Mark Goldin

We have 1 of 16 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Factor XI and XIa Inhibitors: A State-of-the-Art Review Across Clinical Indications

A pattern emerges, where FXI/FXIa inhibition offers a favorable safety profile across multiple settings and high-risk subgroups, yet clear efficacy has so far been established only in secondary prevention of noncardioembolic ischemic stroke over existing antiplatelet strategies.

Ermioni Oikonomou, Mark Goldin, A. Spyropoulos · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.